banner
New Coronary Pneumonia Potentially Effective Drug Gilead Remdesivir (Remdesivir) Apr 06
Gilead's Remdesivir is about to start a study in China, a randomized blinded placebo-controlled phase 3 study of 270 mild/moderate #novelcoronavirus# patients, led by Professor Cao Bin from the China-Japan Friendship Hospital. Expected to start on February 3, 2020. Remdesivir has not been approved for marketing in any country, and its safety and efficacy have not been proven. It is an investigational drug, and there is no data for 2019-nCoV. Although there is currently no antiviral data showing the activity of Remdesivir against 2019-nCoV, its effective data against other coronaviruses give us hope. In in vitro and animal models, Remdesivir has demonstrated activity against the viral pathogens of atypical pneumonia (SARS) and Middle East respiratory syndrome (MERS), which are also coronaviruses and are compatible with 2019-nCoV Structurally very similar. There are also limited clinical data on the emergency use of Remdesivir to treat Ebola-infected patients.
Related news 1: The expert group of the National Health Commission contacted Gilead to apply for the green channel of remdesivir
Regarding the antiviral drug remdesivir developed by the American Gilead Company, which is believed by American scientists to be expected to inhibit the coronavirus, Professor Lu Hongzhou, secretary of the Party Committee of the Shanghai Public Health Clinical Center and an expert group of the Health and Health Commission, said that at present, the expert group The plan and application have been written, reported to the superior department, and directly contacted with Gilead. From the research of American counterparts, the clinical efficacy of this drug is immediate, and remdesivir has also performed outstandingly in the field of MERS virus treatment in the past. Once approved, relevant departments will also open green channels to introduce drugs to benefit Chinese patients.

Related news 2: The "magic drug" Remdesivir in the United States is the most promising for the treatment of new virus pneumonia

The news suggests that a mouse study led by Ralph Baric of the University of North Carolina (published in the journal Nature Communications) tested the combination of interferon beta-1b with the experimental drug Remdesivir made by the US company Gilead Sciences. use. MERS-infected mice with this combination fared better, reducing viral replication and improving lung function. This combination may also be used to treat 2019-nCoV. "Remdesivir was active against every coronavirus we tested, and I would be surprised if it wasn't active against this newly discovered virus," said Vanderbilt University virologist Mark Denison.

Yuan Guoyong, an academician of the Chinese Academy of Engineering and a member of the high-level expert group of the National Health and Medical Commission, said he agreed that Remdesivir is the most promising drug for 2019-nCoV and MERS. However, "this drug is not available in China yet." At present, the drug has completed a phase 2 clinical trial for the treatment of Ebola virus. But as an investigational drug, it has not yet been licensed or approved anywhere in the world. Just a few days ago, a team from the Shanghai Institute of Materia Medica, Chinese Academy of Sciences and the Institute of Immunochemistry, ShanghaiTech University screened and discovered 30 drugs, active natural products and traditional Chinese medicines that may have therapeutic effects on 2019-nCoV. Among them is the currently hotly debated Remdesivir. Remdesivir was developed by Gilead Sciences, a well-known American biopharmaceutical company.

According to media reports, Remdesivir is closely related to atypical pneumonia coronavirus (SARS-CoV), and in vitro and animal models, Remdesivir is effective against both SARS-CoV and MERS-CoV (Middle East respiratory syndrome coronavirus). At present, Gilead is actively communicating with researchers and clinicians in the United States and China regarding the outbreak of novel coronavirus infection in Wuhan, and discussing the possibility of using Remdesivir for treatment, and follow-up plans, including cooperation with regulatory agencies, are also underway middle. Gilead is committed to making the drug available, as appropriate, for compassionate use and controlled clinical trials to support an effective and timely response to viral infections such as Ebola, other filoviruses and viral pathogens globally epidemic.

An academician of the Chinese Academy of Sciences told the "China Science News" that the drug safety of Remdesivir has been clinically verified, and the next thing to discuss is the effectiveness of this drug in the prevention and treatment of new coronavirus pneumonia. Although the drug is not yet on the market, emergency use can still be considered if it is confirmed to be effective in a special period. However, due to the difficulty of synthesizing the drug, it is unlikely to be supplied in large quantities for the time being. At present, domestic scientific research institutions are rapidly screening a batch of effective therapeutic drugs, and Remdesivir is just one of them.


Thchamber stability test chamber can meet the temperature, humidity and vacuum test requirements of the biomedical field. Using advanced technology and excellent accessories, our products are widely recognized by customers for their stable and qualified performance.

Categories

Contact Now

Contact Now

Home

Products

Email

whatsapp